BioSpace News Archive

Verona Pharma plc, announces additional exacerbation* subgroup analyses from the Phase 3 ENHANCE-2 trial in chronic obstructive pulmonary disease.

Bio-Thera Solutions, Ltd. announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics and safety of BAT2606, a proposed biosimilar of Nucala®, to US-sourced and EU-sourced reference product in normal healthy volunteers.

United Therapeutics Corporation announced that three presentations and two posters across its commercial and development portfolio will be presented at the CHEST 2022 Annual Meeting hosted by the American College of Chest Physicians taking place October 16-19, 2022, in Nashville, Tennessee.

Matchpoint Therapeutics, a biotechnology company founded to leverage the power of covalency for the discovery of precision small molecule medicines, launched with $100 million in financing.

BeiGene announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending approval of BRUKINSA® for the treatment of adult patients with chronic lymphocytic leukemia.

Myovant Sciences, announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022.

Phanes Therapeutics, Inc. announced that it has received clearance from the US Food and Drug Administration to commence Phase I studies with PT217, its anti-Delta-like ligand 3 /anti-Cluster of differentiation 47 bispecific antibody being developed for patients with small cell lung cancer and other neuroendocrine cancers.

NanoViricides, Inc., reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2022 with the Securities and Exchange Commission on Thursday, October 13, 2022.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Libtayo® (cemiplimab) as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that four posters will be presented at the upcoming American Society of Nephrology’s (ASN) Kidney Week 2022 Annual Meeting.